Expression of Programmed Death Ligand 1 and Indoleamine 2,3-Dioxygenase in Oral Lichen Planus and Oral Lichenoid Lesions.
IDO
PD‐L1
oral lichen planus
oral lichenoid lesions
oral potentially malignant disorder
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
26 Sep 2024
26 Sep 2024
Historique:
revised:
14
04
2024
received:
29
01
2024
accepted:
18
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
26
9
2024
Statut:
aheadofprint
Résumé
Oral lichen planus (OLP) and oral lichenoid lesions (OLL) are inflammatory T-cell mediated disorders of the oral mucosa (OM). Both are associated with an increased risk of oral squamous cell carcinoma, with OLL possibly having a higher rate of malignant transformation than OLP. Programmed death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO) are immunosuppressive molecules possessing inhibitory effect on T-cells and have been implicated in carcinogenesis. The aim of this study was to examine the expression of PD-L1 and IDO in OLP and OLL. Sixty-eight formalin-fixed, paraffin-embedded tissue samples diagnosed as OLP, compatible with OLP, or OLL were divided into OLP (n = 39) or OLL (n = 29) groups based on both clinical and histopathological diagnostic criteria. Samples of healthy OM (n = 9) served as controls. Samples were immunohistochemically stained for PD-L1 and IDO, and staining distribution and intensity were evaluated. Immunohistochemical expression of PD-L1 was increased in the basal and intermediate layers of epithelium in OLP and in lamina propria in both OLP and OLL compared to controls. OLP and OLL showed increased expression of IDO in epithelium and lamina propria compared to controls. PD-L1 staining intensity in the basal epithelial layer, and IDO staining intensity in lamina propria were increased in OLP compared to OLL. The results indicate that the expression of PD-L1 and IDO increases in OLP and OLL, suggesting that these molecules may play a role in the pathogenesis of both disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Oral lichen planus (OLP) and oral lichenoid lesions (OLL) are inflammatory T-cell mediated disorders of the oral mucosa (OM). Both are associated with an increased risk of oral squamous cell carcinoma, with OLL possibly having a higher rate of malignant transformation than OLP. Programmed death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase (IDO) are immunosuppressive molecules possessing inhibitory effect on T-cells and have been implicated in carcinogenesis. The aim of this study was to examine the expression of PD-L1 and IDO in OLP and OLL.
METHODS
METHODS
Sixty-eight formalin-fixed, paraffin-embedded tissue samples diagnosed as OLP, compatible with OLP, or OLL were divided into OLP (n = 39) or OLL (n = 29) groups based on both clinical and histopathological diagnostic criteria. Samples of healthy OM (n = 9) served as controls. Samples were immunohistochemically stained for PD-L1 and IDO, and staining distribution and intensity were evaluated.
RESULTS
RESULTS
Immunohistochemical expression of PD-L1 was increased in the basal and intermediate layers of epithelium in OLP and in lamina propria in both OLP and OLL compared to controls. OLP and OLL showed increased expression of IDO in epithelium and lamina propria compared to controls. PD-L1 staining intensity in the basal epithelial layer, and IDO staining intensity in lamina propria were increased in OLP compared to OLL.
CONCLUSION
CONCLUSIONS
The results indicate that the expression of PD-L1 and IDO increases in OLP and OLL, suggesting that these molecules may play a role in the pathogenesis of both disorders.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Foundation Finland (Syöpäsäätiö)
Informations de copyright
© 2024 The Author(s). Journal of Oral Pathology & Medicine published by John Wiley & Sons Ltd.
Références
M. S. Alrashdan, N. Cirillo, and M. McCullough, “Oral Lichen Planus: A Literature Review and Update,” Archives of Dermatological Research 308 (2016): 539–551.
A. El‐Howati, M. H. Thornhill, H. E. Colley, and C. Murdoch, “Immune Mechanisms in Oral Lichen Planus,” Oral Diseases 29 (2023): 1400–1415.
M. R. Payeras, K. Cherubini, M. A. Figueiredo, and F. G. Salum, “Oral Lichen Planus: Focus on Etiopathogenesis,” Archives of Oral Biology 58 (2013): 1057–1069.
S. Warnakulasuriya, O. Kujan, J. M. Aguirre‐Urizar, et al., “Oral Potentially Malignant Disorders: A Consensus Report From an International Seminar on Nomenclature and Classification, Convened by the WHO Collaborating Centre for Oral Cancer,” Oral Diseases 27 (2021): 1862–1880.
R. Lu and G. Zhou, “Oral Lichenoid Lesions: Is it a Single Disease or a Group of Diseases?,” Oral Oncology 117 (2021): 105188.
M. Idrees, O. Kujan, K. Shearston, and C. S. Farah, “Oral Lichen Planus Has a Very Low Malignant Transformation Rate: A Systematic Review and Meta‐Analysis Using Strict Diagnostic and Inclusion Criteria,” Journal of Oral Pathology & Medicine 50 (2021): 287–298.
J. W. Li, K. Y. Li, B. W. A. Chan, C. P. McGrath, and L. W. Zheng, “Rate of Malignant Transformation Differs Based on Diagnostic Criteria for Oral Lichenoid Conditions: A Systematic Review and Meta‐Analysis of 24,277 Patients,” Cancers (Basel) 15 (2023): 2537.
R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 Family Revisited,” Annual Review of Immunology 23 (2005): 515–548.
M. Janakiram, U. A. Shah, W. Liu, A. Zhao, M. P. Schoenberg, and X. Zang, “The Third Group of the B7‐CD28 Immune Checkpoint Family: HHLA2, TMIGD2, B7x, and B7‐H3,” Immunological Reviews 276 (2017): 26–39.
M. Azuma, “Co‐Signal Molecules in T‐Cell Activation: Historical Overview and Perspective,” Advances in Experimental Medicine and Biology 1189 (2019): 3–23.
C. Ghosh, G. Luong, and Y. Sun, “A Snapshot of the PD‐1/PD‐L1 Pathway,” Journal of Cancer 12, no. 9 (2021): 2735–2746.
G. H. Du, X. P. Qin, Q. Li, Y. M. Zhou, X. M. Shen, and G. Y. Tang, “The High Expression Level of Programmed Death‐1 Ligand 2 in Oral Lichen Planus and the Possible Costimulatory Effect on Human T Cells,” Journal of Oral Pathology & Medicine 40 (2011): 525–532.
N. Patsoukis, Q. Wang, L. Strauss, and V. A. Boussiotis, “Revisiting the PD‐1 Pathway,” Science Advances 6 (2020): eabd2712.
A. P. Bally, J. W. Austin, and J. M. Boss, “Genetic and Epigenetic Regulation of PD‐1 Expression,” Journal of Immunology 196, no. 6 (2016): 2431–2437.
P. Youngnak‐Piboonratanakit, F. Tsushima, N. Otsuki, et al., “The Expression of B7‐H1 on Keratinocytes in Chronic Inflammatory Mucocutaneous Disease and Its Regulatory Role,” Immunology Letters 94 (2004): 215–222.
G. Zhou, J. Zhang, X. W. Ren, J. Y. Hu, G. F. Du, and X. Y. Xu, “Increased B7‐H1 Expression on Peripheral Blood T Cells in Oral Lichen Planus Correlated With Disease Severity,” Journal of Clinical Immunology 32 (2012): 794–801.
T. Yagyuu, K. Hatakeyama, M. Imada, et al., “Programmed Death Ligand 1 (PD‐L1) Expression and Tumor Microenvironment: Implications for Patients With Oral Precancerous Lesions,” Oral Oncology 68 (2017): 36–43.
J. Ries, A. Agaimy, F. Wehrhan, et al., “Importance of the PD‐1/PD‐L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia,” Biomedicine 9 (2021): 194.
M. Sieviläinen, F. Passador‐Santos, R. Almahmoudi, et al., “Immune Checkpoints Indoleamine 2,3‐Dioxygenase 1 and Programmed Death‐Ligand 1 in Oral Mucosal Dysplasia,” Journal of Oral Pathology & Medicine 47 (2018): 773–780.
X. J. Chen, Y. Q. Tan, N. Zhang, M. J. He, and G. Zhou, “Expression of Programmed Cell Death‐Ligand 1 in Oral Squamous Cell Carcinoma and Oral Leukoplakia Is Associated With Disease Progress and CD8+ Tumor‐Infiltrating Lymphocytes,” Pathology, Research and Practice 215 (2019): 152418.
H. Wu, J. Gong, and Y. Liu, “Indoleamine 2, 3‐Dioxygenase Regulation of Immune Response (Review),” Molecular Medicine Reports 17 (2018): 4867–4873.
S. A. Esmaeili and J. Hajavi, “The Role of Indoleamine 2,3‐Dioxygenase in Allergic Disorders,” Molecular Biology Reports 49 (2022): 3297–3306.
J. C. Mbongue, D. A. Nicholas, T. W. Torrez, N. S. Kim, A. F. Firek, and W. H. Langridge, “The Role of Indoleamine 2, 3‐Dioxygenase in Immune Suppression and Autoimmunity,” Vaccines (Basel) 3 (2015): 703–729.
D. J. Kahler and A. L. Mellor, “T Cell Regulatory Plasmacytoid Dendritic Cells Expressing Indoleamine 2,3 Dioxygenase,” Handbook of Experimental Pharmacology 188 (2009): 165–196.
Z. Zhang, Y. Han, J. Song, et al., “Interferon‐γ Regulates the Function of Mesenchymal Stem Cells From Oral Lichen Planus via Indoleamine 2,3‐Dioxygenase Activity,” Journal of Oral Pathology & Medicine 44 (2015): 15–27.
M. Scheler, J. Wenzel, T. Tüting, O. Takikawa, T. Bieber, and D. von Bubnoff, “Indoleamine 2,3‐Dioxygenase (IDO): The Antagonist of Type I Interferon‐Driven Skin Inflammation?,” American Journal of Pathology 171 (2007): 1936–1943.
E. H. van der Meij and I. van der Waal, “Lack of Clinicopathologic Correlation in the Diagnosis of Oral Lichen Planus Based on the Presently Available Diagnostic Criteria and Suggestions for Modifications,” Journal of Oral Pathology & Medicine 32 (2003): 507–512.
B. Qiao, J. Huang, Z. Mei, A. K. Lam, J. Zhao, and L. Ying, “Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma,” Frontiers in Oncology 10 (2020): 555757.
N. L. Costa, J. A. M. Gonçalves, S. L. G. de Lima, et al., “Evaluation of PD‐L1, PD‐L2, PD‐1 and Cytotoxic Immune Response in Oral Lichen Planus,” Oral Diseases 26 (2020): 1246–1254.
K. Dave, A. Ali, and M. Magalhaes, “Increased Expression of PD‐1 and PD‐L1 in Oral Lesions Progressing to Oral Squamous Cell Carcinoma: A Pilot Study,” Scientific Reports 10 (2020): 9705.